Interferon alfa-2a

干扰素α-2a

Report date: 2022/08/29 20:00:24

Base Information

Drug NameInterferon alfa-2a
Drug Alias NameRoferon ACanferon AAlphaferonRoceron-ArIFN-alpha2a +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellNeoplasms +[4] 
Global Approved IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1986/06/04
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke UniversityF. Hoffmann-La Roche LtdNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellNeoplasms +[4] 

Other Information

ATC CodeL03AB04
Related LinksDrugBankKEGG